Physician profile
Mark A Provenzano
NPI 1982791679
$1,108.99
in general payments reported to CMS, 2019-2025
16 companies · $215 in 2025
The $215 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $299 · 2020: $151 · 2021: $90.21 · 2022: $92.70 · 2023: $65.13 · 2024: $196 · 2025: $215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $476.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $496.79 | 2019-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $200.78 | 2019-2022 | |
| Grifols USA, LLC | $56.34 | 2020-2021 | |
| Abiomed | $41.89 | 2024 | Impella |
| Vifor Pharma, INC. | $40.38 | 2024-2025 | Zemaira |
| Resmed Corp | $39.25 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.89 | 2022-2024 | Glassia |
| Viatris Specialty LLC | $34.62 | 2025 | Yupelri |
| Merck Sharp & Dohme LLC | $31.37 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.54 | 2019 | |
| Ethicon US, LLC | $23.00 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $20.47 | 2024 | Lifevest |
| Chiesi USA, INC. | $18.11 | 2019 | |
| Harmony Biosciences LLC | $16.73 | 2025 | |
| Insmed, INC. | $14.93 | 2025 | Arikayce |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $13.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Provenzano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.